Lundbeck Posts 16% Revenue Growth in H1 2026, Driven by Vyepti and Rexulti — H. Lundbeck A/S (The Lundbeck Foundation)

Event summary

Lundbeck's total revenue grew by 16% CER (13% underlying) to DKK 13,588 million in H1 2026, with U.S. and Europe delivering double-digit growth.
Vyepti® revenue surged 46% CER to DKK 2,865 million, while Rexulti® grew 17% CER to DKK 3,297 million.
EBITDA increased 18% CER to DKK 4,613 million, with adjusted EBITDA up 19% CER to DKK 4,765 million.
The company completed enrollment in the DEEp OCEAN trial for bexicaserin and received FDA Fast Track designation for Lu AH69593.
Lundbeck appointed Tarek Samad as Executive Vice President and Head of R&D, effective September 2026.

The big picture

Lundbeck's strong H1 2026 performance reflects its strategic focus on high-growth products like Vyepti® and Rexulti®, as well as its transition to a partnership model in 27 markets. The company's pipeline advancements and regulatory successes position it well in the competitive neuroscience and migraine treatment sectors. With a clear commercial strategy and a robust balance sheet, Lundbeck is poised to navigate the next phase of its growth trajectory with confidence.

What we're watching

Commercial Momentum: Whether Lundbeck can sustain the strong growth trajectory of Vyepti® and Rexulti® in the second half of 2026.
Pipeline Progress: The pace at which Lundbeck advances its key pipeline assets, particularly bexicaserin and Lu AH69593.
Cost Management: How Lundbeck balances higher R&D costs and cost of sales with its commercial execution strategy.